
|Videos|December 12, 2021
Expert Discusses Add-On Study Design for Ibrutinib as Treatment for Chronic Lymphocytic Leukemia
Lindsey Roeker, MD at assistant attending L1, Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses the study design and the sample demographics.
Advertisement
In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.
She discussed the study design and what the sample demographics were.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Functional Cure of Hepatitis B Infections Among Patients Coinfected With HIV
2
White Bagging, Brown Bagging, and the Pharmacist Caught in the Middle
3
Why Stanford, Harvard, and Yale Are Betting on Psychedelics
4
FDA Expands Casgevy Approval to Children as Young as 2 Years With Sickle Cell Disease or Transfusion-Dependent β-Thalassemia
5










































































































